Amendment: SEC Form SC 13G/A filed by Bionomics Limited

$BNOX
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $BNOX alert in real time by email
SC 13G/A 1 p24-3208sc13ga.htm BIONOMICS LIMITED
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
SCHEDULE 13G/A
 
Under the Securities Exchange Act of 1934
(Amendment No. 2)*
 

Bionomics Limited

(Name of Issuer)
 

Ordinary Shares, no par value per share

(Title of Class of Securities)
 

89854M101**

(CUSIP Number)
 

September 30, 2024

(Date of Event Which Requires Filing of this Statement)
 
 
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
 
¨ Rule 13d-1(b)
x Rule 13d-1(c)
¨ Rule 13d-1(d)
 
(Page 1 of 7 Pages)

 

______________________________

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

**There is no CUSIP number assigned to the Ordinary Shares. The CUSIP number 09063M205 has been assigned to the ADSs of the Issuer, which are quoted on The NASDAQ Global Select Market under the symbol “BNOX.” Each ADS represents one hundred eighty (180) Ordinary Shares.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

CUSIP No. 09063M20513G/APage 2 of 7 Pages

 

1

NAME OF REPORTING PERSON

 

Lynx1 Capital Management LP

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)¨

(b)¨

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5

SOLE VOTING POWER

0

6

SHARED VOTING POWER

98,941,140 ordinary shares (represented by 549,673 ADSs)

7

SOLE DISPOSITIVE POWER

0

8

SHARED DISPOSITIVE POWER

98,941,140 ordinary shares (represented by 549,673 ADSs)

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

98,941,140 ordinary shares (represented by 549,673 ADSs)

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

3.2%

12

TYPE OF REPORTING PERSON

PN

         

 

 

CUSIP No. 09063M20513G/APage 3 of 7 Pages

 

 

1

NAME OF REPORTING PERSON

 

Weston Nichols

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)¨

(b)¨

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

United States of America

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5

SOLE VOTING POWER

0

6

SHARED VOTING POWER

98,941,140 ordinary shares (represented by 549,673 ADSs)

7

SOLE DISPOSITIVE POWER

0

8

SHARED DISPOSITIVE POWER

98,941,140 ordinary shares (represented by 549,673 ADSs)

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

98,941,140 ordinary shares (represented by 549,673 ADSs)

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

3.2%

12

TYPE OF REPORTING PERSON

IN

         

 

 

CUSIP No. 09063M20513G/APage 4 of 7 Pages

 

 

Item 1(a). Name of Issuer.
   
  Bionomics Limited (the “Issuer”)

 

Item 1(b). Address of Issuer’s Principal Executive Offices.
   
 

200 Greenhill Road

Eastwood SA, Australia 5063

 

Item 2(a). Name of Person Filing.
   
  This statement is filed by:  

 

  (i)

Lynx1 Capital Management LP (the “Investment Manager”), a Delaware limited partnership, and the investment manager to Lynx1 Master Fund LP (the “Lynx1 Fund”), with respect to the Ordinary Shares (as defined in Item 2(d) below) directly held by the Lynx1 Fund; and

 

  (ii) Mr. Weston Nichols (“Mr. Nichols”), the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager, with respect to the Ordinary Shares directly held by the Lynx1 Fund.

 

  The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.”
   
  The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Ordinary Shares reported herein.

 

Item 2(b). Address of Principal Business Office.
   
 

Lynx1 Capital Management LP

151 Calle de San Francisco

Suite 200, PMB 1237

San Juan, PR 00901-1607

 

Weston Nichols

c/o Lynx1 Capital Management LP

151 Calle de San Francisco

Suite 200, PMB 1237

San Juan, PR 00901-1607

   
Item 2(c). Place of Organization.
   
 

Investment Manager – Delaware

Mr. Nichols – United States of America

 

Item 2(d). Title of Class of Securities.
   
  Ordinary Shares, no par value per share (the “Ordinary Shares”)

 

CUSIP No. 09063M20513G/APage 5 of 7 Pages

 

 

Item 2(e). CUSIP Number.
   
  There is no CUSIP number assigned to the Ordinary Shares. The CUSIP number 09063M205 has been assigned to the ADSs of the Issuer, which are quoted on The NASDAQ Global Select Market under the symbol “BNOX.” Each ADS represents one hundred eighty (180) Ordinary Shares.

 

Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a:

 

  (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
  (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
  (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
  (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
  (e) ¨ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
  (f) ¨

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

 

  (g) o

A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

 

  (h) ¨

A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);

 

  (i) ¨

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

 

  (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
  (k) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(K).

 

 

If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

specify the type of institution:_________________________________

 

Item 4. Ownership.
   
  The information required by Items 4(a) – (c)  is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each  Reporting Person.

 

CUSIP No. 09063M20513G/APage 6 of 7 Pages

 

 

  The percentages set forth herein as of the date hereof are calculated based upon 3,117,662,864 Ordinary Shares outstanding as of September 17, 2024, as reported in the Issuer’s Annual Report on Form 10-K for the fiscal year ended June 30, 2024, filed with the Securities and Exchange Commission on September 30, 2024.

 

Item 5. Ownership of Five Percent or Less of a Class.
   
  If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:ý

 

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
   
  Not applicable.

 

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
   
  Not applicable.

 

Item 8. Identification and Classification of Members of the Group.
   
  Not applicable.

 

Item 9. Notice of Dissolution of Group.
   
  Not applicable.

 

Item 10. Certification.
   
  By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 

CUSIP No. 09063M20513G/APage 7 of 7 Pages

 

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

 

Date:  November 14, 2024  
 

Lynx1 capital management lp

By: Lynx1 Capital Management GP LLC, its general partner

 

   
  By:  /s/ Weston Nichols
  Name:  Weston Nichols
  Title:    Sole Member
   
   
   
   
  /s/ Weston Nichols
  WESTON NICHOLS

 

 

Get the next $BNOX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BNOX

DatePrice TargetRatingAnalyst
9/28/2023$7.00 → $10.00Buy
Maxim Group
9/28/2023$8.00Neutral → Buy
H.C. Wainwright
1/10/2022$54.00Buy
H.C. Wainwright
1/10/2022$52.00Overweight
Cantor Fitzgerald
1/10/2022$17.00Outperform
Evercore ISI Group
1/10/2022$21.00Buy
Berenberg
More analyst ratings

$BNOX
Press Releases

Fastest customizable press release news feed in the world

See more
  • Bionomics Announces Supreme Court of New South Wales Approves Bionomics' Re-Domiciliation

    ADELAIDE, Australia, and CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company) is pleased to announce that the Supreme Court of New South Wales, Australia ("Court") has today made orders approving the scheme of arrangement in relation to the Company's proposed re-domiciliation from Australia to the United States ("Scheme"), under which Neuphoria Therapeutics Inc., a Delaware corporation ("Neuphoria"), will become the ultimate parent company of Bionomics Limited following the implementation of the Scheme. A copy of the Court's orders with respect to the Scheme was lodged with the Australian Securities & Investments Commission following t

    $BNOX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Results of Scheme Meeting

    ADELAIDE, Australia and CAMBRIDGE, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) ("Bionomics" or the "Company") is pleased to provide the following update on the status of its proposed re-domiciliation from Australia to the United States. Bionomics shareholders have today approved, by the requisite majority, the proposed Scheme of Arrangement in relation to the Company's proposed re-domiciliation from Australia to the United States, under which Neuphoria Therapeutics Inc., a Delaware corporation ("Neuphoria"), will become the ultimate parent company of Bionomics Limited following the implementation of the Scheme of Arrangement. Voting Results In summary: 96%

    $BNOX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Bionomics Publishes the Positive Results from the Phase 2 ATTUNE Study of BNC210 in Patients with Post-Traumatic Stress Disorder in NEJM Evidence

    BNC210 improved PTSD symptom severity at Week 12 with efficacy observed as early as Week 4Company plans to initiate a Phase 3 study of BNC210 in PTSD in H2 2025 ADELAIDE, Australia, and CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that the positive results from its Phase 2 ATTUNE study have been published in the NEJM Evidence. The data were also presented yesterday at the 63ʳᵈ Annual Meeting of the

    $BNOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$BNOX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$BNOX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$BNOX
SEC Filings

See more

$BNOX
Leadership Updates

Live Leadership Updates

See more
  • Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic Growth

    Alan Fisher appointed Chair of the Board of DirectorsTim Cunningham joins as Chief Financial Officer ADELAIDE, Australia and CAMBRIDGE, Mass., July 03, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX, ASX: BNO))) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced key leadership updates to drive its ongoing transformation to a U.S.-focused company, streamline its allocation of capital, and support its next stage of strategic growth. Alan Fisher, currently a non-executive me

    $BNOX
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Bionomics' Half-Year Report

    ADELAIDE, Australia, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited ((ASX: BNO, NASDAQ:BNOX), today announced its FY2023 report for the half-year ended 31 December 2022. This period represented a transformational time for Bionomics in which the Company made great strides on multiple fronts, including progress on advancing the pipeline, raising capital, and implementing strategic corporate initiatives designed to create long-term shareholder value. The Company recently completed its Phase 2 PREVAIL Study to evaluate BNC210 for the acute treatment of Social Anxiety Disorder (SAD). The PREVAIL Study, initiated in January 2022, was a randomised, double-blind, placebo-controlled, multi-ce

    $BNOX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Bionomics appoints Spyridon "Spyros" Papapetropoulos as President and Chief Executive Officer

    ADELAIDE, Australia, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX, ASX: BNO))), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it has appointed Spyridon "Spyros" Papapetropoulos, M.D. as President and Chief Executive Officer (CEO), effective 5 January 2023. Errol B. De Souza, Ph.D., who has been serving as Bionomics' Executive Chairman since November 2018, will continue in his role through 31 December 2022 to ensure a seamless transition, and

    $BNOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$BNOX
Financials

Live finance-specific insights

See more
  • Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA on the Development of BNC210 in Post-Traumatic Stress Disorder

    Successful End-of-Phase 2 (EoP2) meeting with U.S. Food and Drug Administration (FDA) provides a potential path to New Drug Application (NDA) submission for BNC210 for post-traumatic stress disorder (PTSD) with a single Phase 3 trialCompany received favorable FDA feedback on the Phase 3 study design and safety monitoring plans required for registrationCompany plans to initiate the Phase 3 program in Q4 2024A conference call and webcast presentation to discuss the outcomes will be held today at 8:00 a.m. ET, details below ADELAIDE, Australia and CAMBRIDGE, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology com

    $BNOX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Bionomics to Provide a Corporate Update and Discuss End-of-Phase 2 Meeting Outcomes on the Development of BNC210 in PTSD on July 31, 2024

    ADELAIDE, Australia and CAMBRIDGE, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will provide a corporate update and discuss the outcomes of an end-of-Phase 2 (EoP2) meeting with the U.S. Food and Drug Administration regarding the advancement of BNC210 for the treatment of post-traumatic stress disorder (PTSD) into Phase 3 on Wednesday, July 31 at 8:00 am ET. Conference Call and Webcast PresentationDat

    $BNOX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)

    ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity at 12 weeks. Statistically significant secondary endpoints showed improvements in depressive symptoms and sleep. BNC210 was well-tolerated with a safety profile supporting chronic administration. Company plans to engage with the U.S. Food and Drug Administration (FDA) to discuss the registrational path for BNC210 in PTSD. Webcast and conference call will be held today at 8:00 AM EST (10:00 PM AEST). Please click on the link to register: https://lifescievents.com/event/bnox/ ADELAIDE, Australia, and CAMBRIDGE, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE)

    $BNOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$BNOX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more